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Introduction: Patients with systemic lupus erythematosus (SLE) have persistent platelet activation and an increased
risk of thrombotic events, which cannot be accounted for by traditional cardiovascular risk factors. Factor (F)XII has
a potentially important role in thrombus formation and is triggered by activated platelets. We therefore asked
whether the contact system is involved in inflammation and vascular disease (VD) in SLE.
Methods: Fibrin clots were incubated with purified FXII or whole blood, and the activation and regulation of
FXII were studied. Plasma from SLE patients with (n = 31) or without (n = 38) previous VD and from matched
healthy controls (n = 68) were analyzed for the presence of complexes formed between contact system
enzymes and antithrombin (AT) or C1 inhibitor (C1INH) and evaluated with regard to clinical data and
laboratory parameters.
Results: Fibrin clots elicited FXII activation and acted as co-factors for AT. In clotting plasma, the levels of
FXIIa-AT increased, and FXIIa-C1INH decreased. A similar reciprocal relationship existed in SLE patients. FXIIa-AT
was elevated in the SLE patients with a history of VD, while the corresponding levels of factor FXIIa-C1INH
were significantly decreased. FXIIa-AT correlated strongly with platelet parameters. The odds ratio for VD
among the SLE patients was 8.9 if they had low levels of FXIIa-C1INH, 6.1 for those with high levels of FXIIa-AT,
and increased to 23.4 for those with both decreased levels of FXIIa-C1INH and increased levels of FXIIa-AT.
Conclusions: Activation of FXII is elicited by fibrin during thrombotic reactions in vitro and in vivo, and fibrin acts as a
heparin-like co-factor and regulates AT. Patients with SLE had altered levels of FXIIa-serpin complexes, supporting that
the contact system is involved in this disease. FXIIa-serpin complexes are strongly associated with previous VD in SLE
patients, suggesting that these complexes are potential biomarkers for monitoring and assessing the risk of thrombotic
events in SLE.Introduction
Patients with the autoimmune disease systemic lupus er-
ythematosus (SLE) have a drastically increased risk of
thrombotic events, which are a major cause of morbidity
and mortality in these patients. Despite the improved
overall survival in patients with SLE over the last few de-
cades, the risk of death in vascular disease (VD) has not
decreased [1]. Traditional cardiovascular risk factors can
only partly explain this increased risk of VD in SLE [2],
and it is likely that inflammatory mechanisms are also* Correspondence: bo.nilsson@igp.uu.se
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reproduction in any medium, provided the orinvolved. The fact that the pathogenic mechanisms in-
volved are not fully understood has contributed to a lack
of reliable laboratory parameters for evaluating the risk
of thrombotic events.
The contact system, which consists of factor (F) XII,
FXI, prekallikrein, and high molecular weight kininogen
(HK), is a plasma protease cascade that, when activated,
initiates the intrinsic pathway of coagulation (Additional
file 1: Figure S1). It has been considered to be of lesser
importance for hemostasis, since a deficiency in FXII
does not cause any bleeding disorders [3]. Instead, a
pathophysiological role for FXII in thrombosis was pro-
posed after FXII-deficient mice were shown to be defect-
ive in thrombus formation in arterial beds [4]. FXII andd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activation on endothelial cells via the C1q receptor for
globular heads, the urokinase plasminogen activator re-
ceptor, and cytokeratin 1 [5-7].
Recently, we demonstrated that activated human plate-
lets trigger FXII-mediated contact activation [8]. These
results, combined with the observation that patients
with SLE have persistent platelet activation [9-11], led us
to hypothesize that the contact system is involved in in-
flammation and thrombotic conditions associated with
SLE. Kallikrein genes have been shown to be associated
with glomerular basement membrane-specific, antibody-
induced nephritis in mice and with lupus nephritis in
humans [12,13], supporting the possible involvement of
the contact system. A reduction in FXII plasma levels
occurs in SLE patients, concomitant with the appearance
of anti-FXII antibodies [14,15], further corroborating a
role for the contact system in SLE.
The proteases of the contact system circulate in the
blood as zymogens, and after contact activation have
been initiated and enzyme activity has occurred, the en-
zymes quickly form complexes with their inhibitors,
making it very difficult to measure free contact enzymes
in plasma (Additional file 1: Figure S1). Antithrombin
(AT) and C1 inhibitor (C1INH) are members of the ser-
pin protein family [16]. AT is the main inhibitor of the
coagulation cascade and inhibits thrombin, FXa, FIXa, et
cetera. Its activity is regulated by the glycosaminoglycan
(GAG) heparin, which contains a pentasaccharide with a
specific sequence of sulfated monosaccharides that upon
binding to AT augments the antithrombin activity up to
300-fold. Heparin is present in mast cells and basophilic
granulocytes and in the form of heparan sulfate on
endothelial cells, but heparin is not available in blood or
during blood clotting. In contrast to previous reports
stating that FXIIa is mainly inhibited by C1INH, we have
shown that the FXII activation triggered by activated
platelets and during clot formation is regulated by AT.
Only FXII activated by other surfaces (such as artificial
material surfaces) is regulated by C1INH [17], which
suggests that there is a physiological heparin-like mech-
anism by which AT is regulated during blood clotting.
In the present study, we investigated the contact sys-
tem activation in SLE patients by quantifying complexes
formed between contact activation enzymes and the ser-
pins AT and C1INH in blood plasma. These complexes
were evaluated with regard to their potential correlation
with clinical data and with markers of platelet, coagula-
tion, and complement activation. Our primary objective
was to determine whether the contact system is acti-
vated in SLE patients and, based on our previous studies,
to determine whether FXIIa-AT complexes might serve
as a new potential biomarker for platelet activation and
VD in SLE.Methods
Patients
During routine clinical visits to the Department of
Rheumatology at Skåne University Hospital (Lund,
Sweden), 69 SLE patients were recruited for blood sam-
pling and laboratory analyses. All patients fulfilled at
least four American College of Rheumatology (ACR)
classification criteria for SLE [18]. Patients with a known
history of VD were preferentially selected, such that 45%
of the 69 SLE patients had a history of VD, defined in this
study as one or more previous episodes of either myocardial
infarction, arterial thrombosis (12/13 with cerebrovascular
incidents), or venous thrombosis (pulmonary embolism or
deep venous thrombosis), as defined by the Systemic Lupus
International Collaborative Clinics/American College of
Rheumatology Damage Index [19]. The median time be-
tween blood sampling and the last VD event was 8 years.
An overview of the clinical characteristics at the time of
blood sampling is presented in Additional file 2: Table S1
[20]. Healthy age- and sex-matched volunteers with no
history of VD served as controls (n = 68). All of the pa-
tients and the controls were Caucasians, except for two in-
dividuals of Asian origin among the controls and one
individual of Asian and two of Hispanic origin among the
SLE patients. Autoantibodies and complement levels in
serum were measured according to routine analytic proto-
cols used at the Department of Clinical Immunology,
Skåne University Hospital, Lund, Sweden.
Ethical permission
The study was approved by the regional ethics board at
Lund University (LU 378–02). All patients have given
written consent to the study.
Preparation of blood
Fresh human blood, obtained from healthy volunteers
who had received no medication for at least 10 days, was
collected in vacutainer tubes containing either citrate,
ethylenediaminetetraacetic acid (EDTA) (BD Biosciences,
San Jose, CA, USA) or lepirudin (added to a final con-
centration of 50 μg/mL; Schering AG, Berlin, Germany).
Blood was centrifuged at 150 × g for 15 minutes at room
temperature (RT) to produce platelet-rich plasma (PRP)
and twice at 2200 × g for 15 min to produce platelet-poor
plasma (PPP). The plasma was stored at −70°C.
Detection of P-selectin, platelet intracellular proteins, and
platelet-leukocyte complexes
P-selectin (CD62P) exposed on the surface of plate-
lets, IFN-induced transmembrane protein 1 (IFITM1)
and protein kinase, IFN-inducible double stranded RNA
dependent activator (PRKRA), and platelet-leukocyte
complexes were detected by flow cytometry as previously
described by Lood et al. [20].
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The following parameters were measured in EDTA
plasma as previously described: FXIIa-C1INH, FXIa-C1INH,
FXIIa-AT, FXIa-AT [21], thrombospondin-1 (TSP-1), and
thrombin-antithrombin (TAT) [17].
Plasma protein concentration
C1q, C3 and C4 were measured by nephelometry (Immage,
Beckman-Coulter Inc, Hialeach, FL, USA).
Activation of FXII by fibrin clots
Fifty mIU of thrombin (Hoffmann-La Roche, Basel,
Switzerland) was incubated with 0.09, 0.4, or 0.7 μg of fi-
brinogen (Haemochrom Diagnostica, Mölndal, Sweden)
for 10 minutes at 37°C at the bottom of polypropylene
tubes. The resulting clots were referred to as having high
(H), intermediate (I), and low (L) thrombin/fibrinogen
ratios.
Quantification of purified FXIIa activity by chromogenic
assays
The fibrin clots were immediately incubated with 20 μL
of the specific thrombin inhibitor, lepirudin (Schering
AG, Berlin, Germany, 2.5 mg/mL) for 10 minutes at 37°C.
Thereafter, 1 μg of purified FXII (Enzyme Research
Laboratories, Swansea, UK) in 100 μL Tris buffer (50 mM
Tris, 175 mM NaCl, 7.5 mM EDTA, pH 8.4) was added to
the fibrin clots and incubated for an additional 10 minutes
at 37°C: 100 μL of S-2302 (2.5 mM) and S-2238 (1 mM)
(both from Haemochrom Diagnostica) was added separ-
ately and incubated for 5 minutes at 37°C. The reaction
was stopped by adding 100 μL of 20% citric acid, and the
absorbance at 405 nm was measured in the supernatant
after centrifugation at 2200 × g for 2 minutes.
S-2302 was used to quantify FXIIa, and S-2238 as a
control to quantify thrombin since thrombin also can
cleave S-2302. The manufacturer reports substrate turn-
over values (expressed as ΔA/min with protease concen-
tration 4*10-9 M) of 0.480 when S-2238 is used to detect
thrombin activity, and of 0.190 when S-2302 is used to
detect kallikrein activity. Furthermore, the specificity of
FXIIa for S-2302 is substantially lower than that for kal-
likrein [8]. Consequently, data (absorbance) presented in
Figure 1A overestimate the generation of thrombin com-
pared to FXIIa activity.
Quantification of FXIIa-serpin complexes in whole blood
Lepirudin-anticoagulated whole blood (700 μL), PRP
(350 μL), or PPP (350 μL) from five different donors
were added to the fibrin clots. The PPP samples were in-
cubated for 30 minutes, and the others were incubated
for 15 minutes, all at 37°C. The experiments with whole
lepuridin-anticoagulated blood were also repeated in the
presence of 5 μM (final blood concentration) of the lowmolecular weight thrombin inhibitor Melagatran (Astra
Zeneca, Gothenburg, Sweden), which was added to the
fibrin clots 5 minutes before the addition of the blood.
Activation of FXII induced by glass
Citrate anti-coagulated PPP (350 μL) from six different
donors was incubated in glass tubes (borosilicate glass
10 × 75 mm, Kimble-Kontes, Vineland, NJ, USA), with
and without the addition of calcium chloride (CaCl2) at
a final concentration of 10 mM, for 30 minutes at 37°C.
The reaction was blocked by adding EDTA to the sam-
ples to give a final plasma concentration of 10 mM. All
samples were centrifuged at 2200 × g for 15 minutes at
4°C, and the plasma obtained was stored at −70°C until
analyzed for FXII- and FXI-serpin complexes.
Electrophoresis and western blotting
Fibrinogen (Haemochrom Diagnostica) or increasing
concentrations (0.025 to 33.0 μg/mL) of thrombin
(Hoffmann-La Roche) were incubated with purified
human FXII (Enzyme Research Laboratories, 2.5 μg/mL)
for 15 minutes at 37°C. The proteins were analyzed by
SDS-PAGE (10% gels) under reducing conditions followed
by either staining with Coomassie brilliant blue or western
blotting as previously described [22]. The polyvinylidene
fluoride (PVDF) membranes were incubated with sheep
anti-human FXII (the binding site) diluted 1:250. The
membranes were then incubated with horseradish perox-
idase (HRP)-conjugated anti-sheep Ig (Dako, Glostrup,
Denmark) diluted 1:500 and developed with diaminoben-
zidine (Sigma-Aldrich, St Louis, MO, USA).
Statistical analyses
Non-parametric statistical analyses as indicated in the
figure legends were performed using the commercial pro-
gram GraphPad Prism Version 4 (GraphPad Software,
Inc., San Diego, CA, USA). Data in the text section are
presented as medians and interquartile ranges. P-values
<0.05 were considered significant and in the figures are
presented as * = P <0.05, ** = P <0.01 or *** = P <0.0001.
Results
Fibrin activates FXII into FXIIa
Fibrin clots were produced at the bottom of plastic tubes,
and these pre-made clots were incubated with purified
FXII or with blood containing lepirudin. In the purified
system, we observed significant FXII activation induced by
the fibrin network as assessed by the chromogenic sub-
strate S-2302 (Figure 1A). As the sensitivity and specificity
of substrate S-2238 for thrombin is considerably higher
than that of S-2302 for FXIIa, the low enzymatic thrombin
activity detected with the chromogenic substrate S-2238 is
overestimated, and confirmed that the cleavage of S-2302
originated from activated FXII.
Figure 1 Fibrin activates FXII and elicits FXIIa-antithrombin (AT) complex formation in blood. Fibrin clots were produced at the bottom
of tubes. Three different thrombin (thr)/ fibrinogen (fib) ratios generated clots with low (L), intermediate (I), and high (H) density. (A) The clots
or native fibrinogen were incubated with 1 μg of purified FXII, and the enzymatic activity of FXIIa and thrombin was measured using the
chromogenic substrates S-2302 (FXIIa) and S-2238 (thrombin). Data are presented as the means ± standard error of the mean (SEM) (n = 3).
(B-C) The clots, native fibrinogen, and thrombin were incubated with lepirudin-anticoagulated platelet-poor plasma (PPP), platelet-rich plasma
(PRP), and whole blood. The generation of FXIIa-AT (A) and FXIa-AT (B) by the clots in all blood systems was measured by ELISA. Data are presented
as the mean ± SEM (n = 5), and differences compared with the base level are shown (Kruskall-Wallis test with Dunn’s multiple comparison).
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FXIIa-AT and FXIa-AT in PPP, PRP, and whole blood,
with the highest levels in whole blood (Figure 1B-C),
whereas the corresponding C1INH complexes were not
detectable (not shown). The generation of AT complexes
demonstrated that activation of FXII occurred in the
blood/plasma systems and that AT was the preferred
regulator. It also indicated that the activation proceeded
to FXI, as thrombin in the presence of lepirudin could
not contribute to FXI activation. Fibrinogen alone did
not induce AT complexes, and purified thrombin alone
triggered only a minor generation in whole blood.
To further certify that any remaining thrombin did
not lead to FXII activation, lepirudin inhibition was
complemented with the low molecular weight thrombin-
inhibitor Melagatran, which is able to better penetrate
the fibrin clots. Still, no difference in FXIIa generation
was observed (data not shown). We also incubated puri-
fied human FXII in the presence of increasing concen-
trations of thrombin without observing any cleavage of
FXII by SDS-PAGE and/or western blot analysis (data
not shown).
Fibrin promotes AT inhibition of activated FXII
Based on our initial experiment demonstrating that fi-
brin clots activated FXII, we wanted to corroborate thatfibrin could also enhance the affinity or accessibility of AT
for FXIIa. Artificial material-induced FXII activation,
which is regulated by C1INH [17] was triggered in citrated
plasma by the surface in glass tubes. Both FXIIa-C1INH
and FXIa-C1INH were generated without any generation
of the corresponding AT complexes. However, when the
plasma was allowed to coagulate and form fibrin clots,
triggered by re-calcification, the levels of the C1INH-
complexes decreased and, reciprocally, FXIIa-AT and
FXIa-AT were generated. This reflects an increased ten-
dency of AT to inhibit FXIIa and FXIa and a correspond-
ing decline in the C1INH complexes when blood clots
and fibrin are present (Figure 2).
Levels of FXIIa-serpin complexes in SLE patients and
healthy controls
Because patients with SLE exhibit persistent platelet
activation and an increased risk of thrombotic events,
we assessed FXIIa-serpin complexes in an SLE patient
group enriched in patients with a history of VD. Plasma
samples were analyzed for the presence of complexes
formed between FXIIa and FXIa with the serpins AT and
C1INH. Patients with SLE exhibited an altered forma-
tion of FXIIa complexes. In particular, we observed de-
creased FXIIa-C1INH levels in the SLE patients when
compared with baseline levels in control individuals (0.00
Figure 2 A reciprocal relationship exists between the generation of FXIIa-antithrombin (AT) and FXIIa-C1 inhibitor (C1INH) in clotting
plasma. Citrated plasma from healthy donors, with and without the addition of calcium, was incubated in glass tubes, which elicits FXII
activation on the glass surface. The levels of FXIIa-C1INH (A), FXIIa-AT (B), FXIa-C1INH (C), and FXIa-AT (D) were analyzed by sandwich ELISA. Each
line connects data from one individual (n = 6), and statistical significance was determined using Wilcoxon’s signed-rank test.
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In contrast, the levels of FXIIa-AT tended to increase in
the SLE patients (Additional file 3: Table S2), and there
was a negative correlation between FXIIa-C1INH and
FXIIa-AT (rs = −0.24, P = 0.0416). The levels of FXIa-AT
were strongly correlated with FXIIa-AT, and correspond-
ingly, FXIa-C1INH was strongly correlated with FXIIa-
C1INH (Figure 3A-B).
Altered levels of FXIIa-serpin complexes are associated
with previous thrombotic events in SLE patients
To further investigate whether the alterations in FXIIa-
serpin complexes could be involved in the pathogenic
mechanisms leading to thrombotic events in SLE, we
categorized the patients into those with and those with-
out a history of VD. The VD group was further dividedFigure 3 Antithrombin (AT) and C1 inhibitor (C1INH) complexes, respec
(SLE) patients. Complexes formed between activated FXII and FXI and the
samples from SLE patients (n = 69). FXIIa-AT correlated with FXIa-AT (A), wh
coefficients and P-values are given for each calculation.into three subgroups: myocardial infarction (MI), venous
thrombosis (pulmonary embolism or deep venous throm-
bosis), and arterial thrombosis (12/13 with cerebrovascu-
lar incidents) (Additional file 2: Table S1). We observed
distinct differences in the plasma levels of both FXIIa-AT
and FXIIa-C1INH. Increased levels of FXIIa-AT and the
lowest levels (in most cases equivalent to no detected
complexes at all) of FXIIa-C1INH were found in patients
with previous VD (Figure 4). When we compared the
three subgroups of VD, we observed this reciprocal pat-
tern in those patients with previous venous or arterial
thrombosis but not in those with previous MI, although
the difference for FXIIa-AT was only statistically signifi-
cant in the case of the arterial thrombosis subgroup.
We also compared patients with a history of anti-
phospholipid antibody syndrome (APS) to those withouttively, correlated with each other in systemic lupus erythematosus
serpins AT and C1INH were measured by sandwich ELISA in plasma
ereas FXIIa-C1INH correlated with FXIa-C1INH (B). Spearman’s r (rs)
Figure 4 Altered levels of FXIIa-serpin complexes in systemic
lupus erythematosus (SLE) patients with previous vascular
disease (VD). The plasma levels of FXIIa-C1INH (A) and FXIIa-AT
(B) were assessed by sandwich ELISA in plasma from SLE patients
(n = 69) and healthy controls (n = 68). Patients without previous
vascular disease (VD-) were compared with those with previous VD
(VD+). The VD + group was further divided into three subgroups:
myocardial infarction (MI), venous thrombosis (Venous thr), and
arterial thrombosis (Arterial thr). Furthermore, patients with
antiphospholipid antibody syndrome (APS+) were compared with
those without (APS-). In several samples, the levels of FXIIa-C1INH were
below the level of detection (0.01 nM), and these data points are not
visible in the figure. The numbers of individuals in the various groups
with such data are as follows: controls 11/68, VD- 14/38, VD + 24/31, MI
7/10, Venous thr 14/20, Arterial thr 12/13, APS- 25/49, and APS + 13/20.
The lines represent the mean values, and statistical significance was
determined with the non-parametric Kruskall-Wallis test with Dunn’s
multiple comparison (differences when compared with the control are
not shown).
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lower levels of FXIIa-C1INH and higher levels of FXIIa-
AT than did those without APS (not significant).
The generation of FXIIa-AT is strongly linked with
activated platelets
The levels of FXIIa-AT were closely correlated with those
of the two platelet markers: thrombospondin (TSP)-1 in
plasma and platelet P-selectin exposure (Figure 5A-B).
The platelet counts and levels of platelet-leukocytecomplexes were also correlated with those of FXIIa-AT
(Figure 5C-D). None of the above-mentioned markers
allowed us to distinguish between patients with and with-
out previous VD. The levels of IFITM1 and PRKRA,
which have recently been reported to be up-regulated in
SLE patients with VD and in those associated with acti-
vated platelets [17], were positively correlated with those
of FXIIa-AT (Figure 5E-F). The levels of FXIa-AT were
also correlated with all platelet activation markers except
PRKRA (data not shown). The levels of FXIa-C1INH or
FXIa-C1INH were not correlated with any of the platelet
activation markers except for the intracellular levels of
PRKRA and IFITM1, which were negatively correlated
with FXIIa-C1INH (Additional file 4: Table S3).
The plasma levels of C1q, C3, and C4, which are an
indirect and insensitive mirror of complement activation
and immune complex disease, were not correlated to
any of the FXIIa-AT or FXIIa-C1INH complexes. No as-
sociation was found between the FXIIa-serpin complexes
and the systemic lupus erythematosus disease activity
index (SLEDAI) at the time the samples were drawn.
Except for patients treated with warfarin, which tended
to exhibit the highest levels of FXIIa-AT, we observed
no association between any of the AT and C1INH com-
plexes and any of the other most frequently used treat-
ments or with other disease manifestations, such as
glomerulonephritis or arthritis (data not shown). It should
be noted that all of the warfarin-treated patients exhibited
previous thrombosis except for six patients who all had
very low levels of FXIIa-AT, which reflects that warfarin
lowers the risk of thrombosis, and thereby decreases the
FXIIa-AT levels.
The alterations in the levels of FXIIa-serpin complexes
points to new biomarkers for VD risk evaluation in SLE
patients
The odds ratios (OR) for VD with respect to the two types
of FXIIa-serpin complexes (Table 1) were calculated.
Based on receiver operating characteristic (ROC) curve
analyses and the Youden index, the cutoff value for FXIIa-
C1INH was set to <0.01 nM, which corresponded to the
detection limit of the assay, and for FXIIa-AT to >0.40
nM, which corresponded to the 90% percentile of the con-
trols. The OR for VD was 8.9 if the levels of FXIIa-C1INH
were low and 6.1 if the levels of FXIIa-AT were high. If
the complexes were combined and both the criteria were
fulfilled, the OR increased to 23.4. When the OR was cal-
culated in this material with respect to the occurrence of
anti-cardiolipin antibodies, the OR was 2.0, but there was
no significant difference in the VD outcome.
Discussion
We have previously shown that activation of platelets in-
duces activation of FXII that is regulated by AT, which is
Figure 5 The occurrence of FXIIa-antithrombin (AT) is clearly linked to platelet activation. Plasma levels of thrombospondin 1 (TSP-1)
(A), platelet expression of P-selectin (CD62P) (B), platelet count (C), platelet-leukocyte complexes (D), platelet intracellular levels of the type I
IFN-regulated proteins (IFITM1) and protein kinase IFN-inducible double-stranded RNA dependent activator (PRKRA) (E and F), all parameters
reflecting platelet activation, were assessed in systemic lupus erythematosus (SLE) patients (n = 69). All parameters were shown to statistically
correlate with FXIIa-AT tested with Spearman’s rank-order correlation coefficients (rs).
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and FXIa-AT complexes in clotted blood [8,17]. In the
present work, we demonstrate that fibrin formation is an
essential mechanism that drives the activation of FXII
and the subsequent formation of FXIIa-AT complexes.Table 1 FXIIa-serpin complexes and aCL antibodies in
association with VD in SLE patients
VD-, n (%) VD+, n (%) P-valuea OR (95% CI)
All 38 (55) 31 (45)
FXIIa-C1INH
<0.01 nMb
14 (37) 24 (77) P <0.0001 8.9 (2.8, 28.5)
FXIIa-AT
>0.40 nMc
4 (11) 13 (42) P = 0.0043 6.1 (1.7, 21.6)
Both low
FXIIa-C1INH
1 (3) 12 (39) P <0.0001 23.4 (2.8, 194)
and high FXIIa-AT
aCL antibodies 12 (32) 15 (48) n.s. 2.0 (0.8, 5.4)
SLE, systemic lupus erythematosus; VD, vascular disease; F, factor; C1INH, C1
inhibitor; AT, antithrombin; Acl, anti-cardiolipin; OR, odds ratio; n.s., not
significant. aFisher's exact test; b0.01 nM = detection limit of the assay;
c0.40 nM = 90% percentile of controls.We also found that an SLE patient group enriched in
patients with previous VD exhibited altered levels of
FXIIa-complexes when compared with healthy controls
and that increased levels of FXIIa-AT and decreased
levels of FXIIa-C1INH were associated with VD and pre-
vious thrombotic events. These results are in line with
recent data indicating an important role of FXII in
thrombus formation.
In the present study, we asked whether fibrin clots
could trigger FXII activation and if so, how it was regu-
lated. Preformed fibrin clots were shown to activate
purified FXII, and when incubated in blood, there was a
substantial generation of both FXIIa-AT and FXIa-AT
complexes, similar to what we previously have shown to
occur in clotting blood. Thrombin cannot activate FXII,
and with the simultaneous use of the antithrombin com-
pounds melagatran and lepirudin, we verified that acti-
vation of FXII was not mediated by thrombin. These
findings are consistent with a recent study demonstrating
that fibrin binds FXII and α-FXIIa [24]. Complementing
these findings, our data obtained using chromogenic
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strate that FXII is specifically activated by the preformed
fibrin clots.
We also observed a reciprocal relationship between
the generation of FXIIa-AT and FXIIa-C1INH complexes
in plasma if fibrin generation and clotting were triggered
in vitro. Fibrin formation promoted the generation of AT
complexes and seemed to increase the affinity, or the
accessibility, of AT for FXIIa and FXIa, competing out
C1INH and leading to the generation of FXIIa-AT and
FXIa-AT complexes. Thus, fibrin seems to act as a physio-
logical heparin-like co-factor.
In previous studies, we and others, have shown that
platelet activation and an increased generation of fibrin
continuously occurs in vivo in SLE, particularly in those
patients with a history of VD [9,22,25,26]. Given the
strong association between FXIIa-AT levels in plasma
and platelet activation in vitro [8,17], we expected to
find increased levels of these complexes in SLE patients,
with the highest levels in those with VD. When SLE
patients with and without a history of VD were com-
pared, we found significantly increased levels of FXIIa-
AT in those who had VD. Higher levels of FXIIa-AT
were found particularly in those patients with previous
venous and arterial thrombosis. With the exception of
the previously reported IFITM1 and PRKRA in plate-
lets [20], none of the other markers of platelet activa-
tion that we examined allowed us to differentiate between
the patients with previous VD and those without. A
history of previous anti-cardiolipin antibodies was also
uninformative.
Similar to the situation in the in vitro experiments,
the high FXIIa-AT levels in vivo were reciprocal to
those of FXIIa-C1INH, which were decreased in the
SLE patients and particularly in those with a history
of thrombotic events, where in many cases no FXIIa-
C1INH could be detected. The decrease in FXIIa-
C1INH was corroborated by a report of a study that
investigated patients with coronary heart disease and
stroke [27]. In that study, patients with VD exhibited
significantly lower levels of FXIIa-C1INH complexes,
particularly in the case of smokers, than did controls.
Based on our in vitro experiments where fibrin gave rise
to a switch from FXIIa-C1INH to FXIIa-AT complexes
(see above), the generation of soluble fibrin and micro-
thrombi, which preferentially promote AT regulation of
FXIIa, is a possible cause of the decreased FXIIa-C1INH
levels.
Further support for a link between platelet-induced
fibrin generation and the generation of AT complexes
was that both FXII-AT and FXIa-AT but none of the
C1INH complexes were correlated with several platelet
parameters, for example, TSP-1, P-selectin exposure, plate-
let count, and platelet-leukocyte complexes. Moreover,FXIIa-AT levels were correlated with the two type I IFN-
regulated proteins, IFITM1 and PRKRA, detected in plate-
lets. The up-regulation of these two proteins in platelets
has previously been shown to be associated with platelet
activation and VD in SLE [20].
The levels of FXIIa-AT were strongly correlated with
those of FXIa-AT in the SLE patients. This was also the
case for the corresponding C1INH complexes. These
results suggest that the regulation of the protease with
AT or C1INH occurred under different circumstances.
The results may indicate that the initial activation of
FXII occurred at different sites, where clot formation
may represent the milieu where AT complexes are
formed. Similar to our in vitro experiments, we also ob-
served a negative correlation between FXIIa-AT and
FXIIa-C1INH complexes in the SLE patients. This fur-
ther emphasizes different mechanisms of FXII activation
and complex formation, and the likelihood that soluble
fibrin or microthrombi may be the explanation for the
altered ratios of FXIIa complexes. Furthermore, these
in vivo data corroborate that fibrin possesses heparin-
like AT co-factor activity.
Today, assessment of anti-cardiolipin antibodies and
lupus anticoagulants is the state-of-the-art approach to
evaluate the risk of thrombotic events in SLE patients
[23]. Anti-phospholipid antibodies are linked to, but not
strictly correlated with VD and thrombotic events, as is
also reflected in the present but limited study. By itself,
our analytic approach is not sufficiently specific and
needs to be complemented with other analyses to produce
an accurate assessment of the risk of future thrombotic
events. FXIIa-serpin complexes, which were strongly asso-
ciated with VD, may be emerging analyses for the future
evaluation of the risk of thrombotic events in SLE pa-
tients. However, these analyses need to be validated in
prospective studies before they can be used alone or in
combination as a means for gauging the risk of throm-
botic events in SLE.
Conclusion
This study shows that activation of the contact system is
involved in the pathophysiology of SLE and that the acti-
vation of the contact system is likely to be triggered by
fibrin. We show that the formation of FXIIa-AT com-
plexes is associated with thrombotic events and that
generation of these complexes represents a promising
potential biomarker for evaluation of the risk of throm-
botic events in SLE.
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weight kininogen functions as a co-factor for kallikrein and factor XI by
facilitating their binding to surfaces. The serpins C1 inhibitor and
antithrombin are able to inhibit the activated proteases of the contact
system by forming irreversible complexes with them. Contact activation
initiated by biomaterial surfaces, and presumably also endothelial cells, is
regulated by C1 inhibitor, whereas activation induced by activated platelets
and occurring in clot formation is regulated by antithrombin. F, factor; a,
activated; HK, high molecular-weight kininogen; PK, prekallikrein; KK,
kallikrein; BK, bradykinin; C1INH, C1 inhibitor; AT, antithrombin.
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Additional file 4: Table S3. Correlations of FXIIa- C1 inhibitor (C1INH),
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